Advanced Filters
noise

Nephropathy Clinical Trials

A listing of Nephropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 369 clinical trials
N Nan Su

A Study of CM310 in Subjects With Moderate to Severe Asthma

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, …

12 - 75 years of age Both Phase 2/3

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.

18 - 80 years of age Both Phase 2
R Research Coordinator

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.

18 - 60 years of age Both Phase N/A
G Guillaume Lezmi, Doctor (PHU)

Defining the Severe Paediatric Asthma Endotype

The primary objective of this project is to extensively characterize the endotypes of pre-schoolers (0 to 6 years) and school-age children (6 to 12 years) with SA using an integrated approach, combining a description of their phenotype (asthma symptoms, atopy, and lung function) associated with histological (airway inflammation and remodelling), …

- 12 years of age Both Phase N/A
R Rod A Rahimi, MD PhD

Lung-Resident Memory Th2 Cells in Asthma

Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype. ~5-10% of effector Th2 cells recruited into the lung give rise to long-lived tissue resident memory cells that are poised to …

18 - 55 years of age Both Phase N/A
E Eda Gülbetekin

Effect of Halotherapy in Children With Asthma

Introduction: Asthma is a chronic respiratory disease that can affect all age groups and is characterized by episodic and reversible wheezing, shortness of breath, chest tightness and cough attacks. According to a 2016 report by the United States Department of Disease Control and Prevention (CDC), the prevalence of asthma was …

4 - 10 years of age Both Phase 1
M Michelle Spano

Asthma Link Effectiveness Trial: Cluster Randomized Controlled Trial

The goal of this cluster RCT is to determine the effectiveness of Asthma Link, a school supervised asthma therapy program, compared with an educational asthma workbook, in improving asthma symptoms for children with poorly controlled asthma aged 5-14.

5 - 14 years of age Both Phase N/A
E Emily Lien, MS

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it aims to answer are Could the LTh(αK) intranasal treatment improve the clinical condition of these patients? Could patients self-administrate LTh(αK) via the intranasal route? Is the LTh(αK) at multiple doses safe …

20 - 80 years of age Both Phase 2
K Katherine Spaulding

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to …

18 - 75 years of age Both Phase 4

A Study of CM326 in Subjects With Moderate to Severe Asthma

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week treatment period, and …

18 - 75 years of age Both Phase 2

Rewrite in simple language using AI